Codex DNA Inc
Change company Symbol lookup
Select an option...
DNAY Codex DNA Inc
CAC Camden National Corp
RE Everest Re Group Ltd
URRNF Twenty Seven Co Ltd
TWLV Twelve Seas Investment Co II
FLO Flowers Foods Inc
CAJ Canon Inc
WPC WP Carey Inc
PPT Putnam Premier Income Trust
GME GameStop Corp
Go

Company profile

Codex DNA, Inc. is a synthetic biology company. The Company is focused on enabling researchers to build or write synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) that is ready to use in downstream synthetic biology enabled markets. Its synthetic biology solutions include the BioXp 3250 system, BioXp kits, BioXp portal, Benchtop reagent kits and Biofoundry services. Its BioXp system is an end-to-end automated workstation. The Company's BioXp kits contain all the necessary building blocks and reagents, including the Company's Gibson Assembly branded reagents. The BioXp portal is a user-friendly online portal that offers a guided workflow and design tools. Benchtop reagent kits contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system. Its Biofoundry services enable a customer to order and receive any of the BioXp system endpoint-ready products.

Closing Price
$7.30
Day's Change
0.44 (6.41%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.41
Day's Low
6.85
Volume
(Light)
Volume:
146,791

10-day average volume:
333,273
146,791

Display:

Providers:

UpdateCancel
6 providers
January 18, 2022
Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

-- Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virus -- Initial performance results show potentially significant...(Globe Newswire)

January 10, 2022
Thinking about buying stock in Tilray, Avinger, Reliance Global, BioCryst Pharmaceuticals, or Codex DNA?

InvestorsObserver issues critical PriceWatch Alerts for TLRY, AVGR, RELI, BCRX, and DNAY. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA's Novel Enzymatic DNA Synthesis Technology for Pfizer's use in its Research and Development of mRNA-based Vaccines and Biotherapies

-- Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA's novel enzymatic DNA synthesis (EDS) technology Codex DNA, Inc. (NASDAQ: DNAY), a leader in the development of automated solutions for...(Globe Newswire)

December 31, 2021
Thinking about buying stock in Kiora Pharmaceuticals, Tencent Music Entertainment, Naked Brand, Flotek Industries, or Codex DNA?

InvestorsObserver issues critical PriceWatch Alerts for KPRX, TME, NAKD, FTK, and DNAY. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

December 30, 2021
Thinking about buying stock in Insignia Systems, Codex DNA, Energy Focus, Himax Technologies, or TRACON Pharmaceuticals?

InvestorsObserver issues critical PriceWatch Alerts for ISIG, DNAY, EFOI, HIMX, and TCON. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

December 29, 2021
Thinking about buying stock in Flotek Industries, NRX Pharmaceuticals, Medallion Financial, Reliance Global, or Codex DNA?

InvestorsObserver issues critical PriceWatch Alerts for FTK, NRXP, MFIN, RELI, and DNAY. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

December 23, 2021
Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant

Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced the release of a new full-length synthetic genome of the SARS-CoV-2 virus for the highly mutated and contagious Omicron variant (B.1.1.529...(Globe Newswire)

November 22, 2021
Codex DNA and RNAimmune Announce Collaboration to Optimize Development of Future mRNA Synthesis and Delivery Kits

Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, and RNAimmune, a leading biotech company with expertise in messenger RNA (mRNA) design and delivery technologies, today announced the initiation of work...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.